Safety and Tolerability of the Nutritional Supplement, Nicotinamide Riboside, in Systolic Heart Failure

营养补充剂烟酰胺核苷治疗收缩性心力衰竭的安全性和耐受性

基本信息

  • 批准号:
    9113264
  • 负责人:
  • 金额:
    $ 11.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-06-01 至 2018-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Medical care of heart failure (HF) has been stagnant for the past 20 years; innovative therapy is urgently needed. A novel therapeutic target, mitochondrial dysfunction, has been implicated in multiple diseases, including heart failure. However, there currently is no specific treatment for mitochondrial dysfunction in human heart failure or any other disease. Mitochondria-based therapy development has been hampered both by limited understanding of how mitochondrial impairment causes cardiac dysfunction, and by a lack of interventions shown to improve mitochondrial function. Recently, we demonstrated in a murine model, that impaired mitochondrial oxidative phosphorylation led to an increased myocardial NADH/NAD+ ratio and increased mitochondrial protein acetylation, without affecting mitochondrial ROS production or ATP synthesis. These changes rendered the heart susceptible to chronic stresses, which accelerated the development of heart failure. We observed a similar increase of NADH/NAD+ ratio and increase in protein acetylation in animal models of heart failure due to chronic pressure overload with no prior mitochondrial dysfunction. Supplying the NAD+ precursor, nicotinamide mononucleotide (NMN), to these mice normalized the NADH/NAD+ ratio, prevented increased mitochondrial protein acetylation and improved cardiac function. Though NMN is not orally bioavailable, we and others have shown that oral supplementation with nicotinamide riboside (NR), the precursor from which NMN is produced, also decreases (normalizes) tissue NADH/NAD+ ratio and improves mitochondrial function in mouse models. These animal model results suggest a conceptually innovative mechanism linking mitochondrial dysfunction to the development and progression of heart failure that is distinct from the existing hypotheses of oxidative stress and energy starvation. Thus, we hypothesize that oral supplementation with NR will improve the NADH/NAD+ ratio caused by mitochondrial dysfunction during chronic stresses, and improve functional capacity and ventricular function in systolic heart failure. We therefore propose a first-in-human, safety and tolerability trial of the nutritional supplement, nicotinamide riboside (NR) in 30 participants wit clinically-stable, systolic heart failure. NR is a relative of niacin, but a closer relative of nicotinamide which, unlike niacin, does not induce flushing or pruritis and has no effect on lipid levels. NR does not induce insulin resistance or dysglycemia in mouse models. Thus, NR would potentially be cheap, safe, well-tolerated and readily available. The application is in response to the program announcement of "Nutrition and Diet in the Causation, Prevention, and Management of Heart Failure" as NR has recently been approved for human use as a health supplement. As NR has not been used therapeutically in heart failure patients, we will utilize the R21 mechanism to support a pilot study with the following aims: 1) to determine the safety and tolerability of NR in patients with clinically-stable, systolic heart failure (LVEF <40%); 2) to determine whether, at the doses employed, NR has measureable effects on leukocyte NAD+ level and NADH/NAD+ ratio; and 3) to explore the potential range of effects of NR supplementation on heart failure surrogate endpoints.
描述(由申请人提供):心力衰竭(HF)的医疗保健在过去20年中一直停滞不前;迫切需要创新的治疗方法。线粒体功能障碍是一种新的治疗靶点,与包括心力衰竭在内的多种疾病有关。然而,目前还没有针对人类心力衰竭或任何其他疾病的线粒体功能障碍的特异性治疗方法。由于对线粒体损伤如何导致心功能障碍的理解有限,以及缺乏表明可以改善线粒体功能的干预措施,线粒体治疗的发展受到了阻碍。最近,我们在小鼠模型中证明,线粒体氧化磷酸化受损导致心肌NADH/NAD+比例增加,线粒体蛋白乙酰化增加,但不影响线粒体ROS生成或ATP合成。这些变化使心脏容易受到慢性压力的影响,从而加速了心力衰竭的发展。我们观察到,在没有线粒体功能障碍的慢性压力负荷心力衰竭动物模型中,NADH/NAD+比值和蛋白质乙酰化也有类似的增加。向这些小鼠提供NAD+前体烟酰胺单核苷酸(NMN),使NADH/NAD+比例正常化,防止线粒体蛋白乙酰化增加,改善心功能。虽然NMN不是口服生物可利用的,但我们和其他人已经证明,在小鼠模型中,口服补充烟酰胺核苷(NR) (NMN产生的前体)也可以降低(正常化)组织NADH/NAD+比率并改善线粒体功能。这些动物模型的结果表明,线粒体功能障碍与心力衰竭的发展和进展之间的概念创新机制不同于现有的氧化应激和能量饥饿假说。因此,我们假设口服NR可以改善慢性应激时线粒体功能障碍引起的NADH/NAD+比值,改善收缩期心力衰竭时的功能容量和心室功能。因此,我们建议在30名临床稳定的收缩期心力衰竭患者中进行营养补充剂烟酰胺核苷(NR)的首次人体安全性和耐受性试验。NR是烟酸的近亲,但是烟酰胺的近亲,与烟酸不同,烟酰胺不会引起潮红或瘙痒,对脂质水平没有影响。在小鼠模型中NR不诱导胰岛素抵抗或血糖异常。因此,NR可能是便宜、安全、耐受性良好且容易获得的。应用程序响应于

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kevin D. O'Brien其他文献

16 Weeks of Diabetogenic Diet are Sufficient To Induce Cardiac Hypertrophy and Fibrosis in a Murine Model of Diet-Induced Insulin Resistance and Cardiomyopathy
  • DOI:
    10.1016/j.cardfail.2012.06.074
  • 发表时间:
    2012-08-01
  • 期刊:
  • 影响因子:
  • 作者:
    Antonio Sta Teresa;Jinkyu Kim;Tomasz Wietecha;Kelly Hudkins;Charles E. Alpers;Kevin D. O'Brien
  • 通讯作者:
    Kevin D. O'Brien
Patient-carried card prompts vs computer-generated prompts to remind private practice physicians to perform health maintenance measures.
患者携带的卡片提示与计算机生成的提示,提醒私人执业医生执行健康维护措施。
  • DOI:
    10.1001/archinte.1994.00420170105010
  • 发表时间:
    1994
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Robert C. Turner;J. G. Peden;Kevin D. O'Brien
  • 通讯作者:
    Kevin D. O'Brien
Metformin, but not Diet-Induced Weight Loss, Decreases Myocardial Fibrosis in a Murine Model of Diet-Induced Insulin Resistance and Cardiomyopathy
  • DOI:
    10.1016/j.cardfail.2012.06.021
  • 发表时间:
    2012-08-01
  • 期刊:
  • 影响因子:
  • 作者:
    Tomasz Wietecha;Jinkyu Kim;Antonio Sta Teresa;Kelly Hudkins;Charles E. Alpers;Kevin D. O'Brien
  • 通讯作者:
    Kevin D. O'Brien
DIVERGENT EFFECTS OF VASODILATORS ON CARDIAC HYPERTROPHY AND INFLAMMATION IN A MURINE MODEL OF DIABETIC CARDIOMYOPATHY
  • DOI:
    10.1016/s0735-1097(11)60193-9
  • 发表时间:
    2011-04-05
  • 期刊:
  • 影响因子:
  • 作者:
    Kevin D. O'Brien;Warangkana Pichaiwong;Jinkyu Kim;Antonio Haw;Bardia Askari;Tomasz Wietecha;Kelly Hudkins-Loya;Charles E. Alpers
  • 通讯作者:
    Charles E. Alpers
222: Lipoproteins in the Prediction of Coronary Artery Calcium (CAC) as Modified by Age in the Multi-Ethnic Study of Atherosclerosis (MESA)
  • DOI:
    10.1016/j.jacl.2008.04.039
  • 发表时间:
    2008-06-01
  • 期刊:
  • 影响因子:
  • 作者:
    Pathmaja Paramsothy;Gregory L. Burke;Ronit Katz;Kevin D. O'Brien;David S. Owens;Jeffrey L. Probstfield
  • 通讯作者:
    Jeffrey L. Probstfield

Kevin D. O'Brien的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kevin D. O'Brien', 18)}}的其他基金

Mechanistic Studies of NAD+/NADH in Human Heart Failure
NAD/NADH 在人类心力衰竭中的作用机制研究
  • 批准号:
    10242151
  • 财政年份:
    2019
  • 资助金额:
    $ 11.59万
  • 项目类别:
Energy metabolism and NAD+/NADH in Right Ventricular Failure
右心室衰竭中的能量代谢和 NAD /NADH
  • 批准号:
    10629552
  • 财政年份:
    2019
  • 资助金额:
    $ 11.59万
  • 项目类别:
Mechanistic Studies of NAD+/NADH in Human Heart Failure
NAD/NADH 在人类心力衰竭中的作用机制研究
  • 批准号:
    10006334
  • 财政年份:
    2019
  • 资助金额:
    $ 11.59万
  • 项目类别:
Mechanistic Studies of NAD+/NADH in Human Heart Failure
NAD/NADH 在人类心力衰竭中的作用机制研究
  • 批准号:
    10470297
  • 财政年份:
    2019
  • 资助金额:
    $ 11.59万
  • 项目类别:
Mechanistic Studies of NAD+/NADH in Human Heart Failure
NAD/NADH 在人类心力衰竭中的作用机制研究
  • 批准号:
    10908777
  • 财政年份:
    2019
  • 资助金额:
    $ 11.59万
  • 项目类别:
Plaque Inflammation and Dysfunctional HDL in AIM-HIGH
AIM-HIGH 中的斑块炎症和 HDL 功能障碍
  • 批准号:
    8300144
  • 财政年份:
    2008
  • 资助金额:
    $ 11.59万
  • 项目类别:
Plaque Inflammation and Dysfunctional HDL in AIM-HIGH
AIM-HIGH 中的斑块炎症和 HDL 功能障碍
  • 批准号:
    7615104
  • 财政年份:
    2008
  • 资助金额:
    $ 11.59万
  • 项目类别:
Plaque Inflammation and Dysfunctional HDL in AIM-HIGH
AIM-HIGH 中的斑块炎症和 HDL 功能障碍
  • 批准号:
    8067139
  • 财政年份:
    2008
  • 资助金额:
    $ 11.59万
  • 项目类别:
Plaque Inflammation and Dysfunctional HDL in AIM-HIGH
AIM-HIGH 中的斑块炎症和 HDL 功能障碍
  • 批准号:
    7822854
  • 财政年份:
    2008
  • 资助金额:
    $ 11.59万
  • 项目类别:
Plaque Inflammation and Dysfunctional HDL in AIM-HIGH
AIM-HIGH 中的斑块炎症和 HDL 功能障碍
  • 批准号:
    7462430
  • 财政年份:
    2008
  • 资助金额:
    $ 11.59万
  • 项目类别:

相似海外基金

Determining 4-Dimensional Foot Loading Profiles of Healthy Adults across Activities of Daily Living
确定健康成年人日常生活活动的 4 维足部负荷曲线
  • 批准号:
    2473795
  • 财政年份:
    2024
  • 资助金额:
    $ 11.59万
  • 项目类别:
    Studentship
Developing a trunk function assessment for hemiplegics. -For improving activities of daily living-
开发偏瘫患者的躯干功能评估。
  • 批准号:
    23K10540
  • 财政年份:
    2023
  • 资助金额:
    $ 11.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Relation with the activities of daily living and the subjective values among people with social withdrawal
社交退缩者日常生活活动与主观价值观的关系
  • 批准号:
    23K16596
  • 财政年份:
    2023
  • 资助金额:
    $ 11.59万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
CRII: RI: Understanding Activities of Daily Living in Indoor Scenarios
CRII:RI:了解室内场景中的日常生活活动
  • 批准号:
    2245652
  • 财政年份:
    2023
  • 资助金额:
    $ 11.59万
  • 项目类别:
    Standard Grant
Sources of vulnerability among those using homecare despite having no limitations in Activities of Daily Living. An intersectionality analysis
尽管日常生活活动没有限制,但使用家庭护理的人的脆弱性来源。
  • 批准号:
    499112
  • 财政年份:
    2023
  • 资助金额:
    $ 11.59万
  • 项目类别:
    Operating Grants
Association between Nursing Care and Prognosis and Activities of Daily Living in Acute Stroke patients by using Big Data.
利用大数据研究急性脑卒中患者的护理与预后和日常生活活动的关系。
  • 批准号:
    23K16412
  • 财政年份:
    2023
  • 资助金额:
    $ 11.59万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Synergizing home health rehabilitation therapy to optimize patients’ activities of daily living
协同家庭健康康复治疗,优化患者的日常生活活动
  • 批准号:
    10429480
  • 财政年份:
    2022
  • 资助金额:
    $ 11.59万
  • 项目类别:
Effects of a model of nurses-occupational therapists collaborative practice on activities of daily living in elderly patients
护士-职业治疗师合作实践模式对老年患者日常生活活动的影响
  • 批准号:
    22K17540
  • 财政年份:
    2022
  • 资助金额:
    $ 11.59万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Assessing a Novel Virtual Environment that Primes Individuals Living with AD/ADRD to Accomplish Activities of Daily Living.
评估一种新颖的虚拟环境,该环境可以帮助 AD/ADRD 患者完成日常生活活动。
  • 批准号:
    10668160
  • 财政年份:
    2022
  • 资助金额:
    $ 11.59万
  • 项目类别:
Synergizing home health rehabilitation therapy to optimize patients’ activities of daily living
协同家庭健康康复治疗,优化患者的日常生活活动
  • 批准号:
    10621820
  • 财政年份:
    2022
  • 资助金额:
    $ 11.59万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了